All
All

What are you looking for?

All
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”
EN
ČeštinaEnglish

Possibilities of Silver Nanoparticles Potentiated Antibiotherapy in the Treatment of Serious Bacterial Infections – in vitro and in vivo study

Project goals

Bacterial resistance increasingly limits antibiotic effectiveness, and concurrently significantly complicates antibiotic therapy of systemic infections, e.g. sepsis, resulting in higher morbidity and mortality of patients. A promising way to overcome this problem is a combination of classic antibiotics with silver nanoparticles (NPs). Thanks to non-specific activity of silver NPs, synergistic combination enables strong and effective antibacterial activity at low doses both of antibiotics and silver NPs and at the same time limits development of bacterial resistance. The aim of this project is in vitro and in vivo applied research focused on possible use of conventional antibiotics potentiated with silver NPs in therapy of systemic infection in clinically relevant large animal model of sepsis.

Keywords

rezistenceresistancesepsesepsisinfekceinfectionbakteriebacteriaNanočásticein vivoin vitroin vivoin vitronanoparticleAntibiotikumAntibioticsilverantibacterial activitysynergystříbroantibakteriální aktivitasynergie

Public support

  • Provider

    Ministry of Health

  • Programme

    —

  • Call for proposals

    SMZ0202000001

  • Main participants

    Univerzita Palackého v Olomouci / Přírodovědecká fakulta

  • Contest type

    VS - Public tender

  • Contract ID

    NU20-05-00165

Alternative language

  • Project name in Czech

    Možnosti nanočásticemi stříbra potencované antibioterapie v léčbě závažných bakteriálních infekcí – studie in vitro a in vivo

  • Annotation in Czech

    Bakteriální rezistence stále více limituje účinnost antibiotik a rovněž velmi výrazně komplikuje schopnost léčby závažných systémových infekcí, například sepsí, což způsobuje nárůst morbidity a mortality pacientů. Slibnou možností jak překonat tento problém je kombinace klasických antibiotik s nanočásticemi stříbra. Takováto synergická kombinace umožňuje díky nespecifické aktivitě nanostříbra vysoce efektivní antibakteriální účinnost za nízkých koncentrací jak antibiotika, tak i nanočástic stříbra a současně limituje vývoj bakteriální rezistence. Cílem tohoto projektu je in vitro a in vivo aplikovaný výzkum zaměřený na možnosti použití nanočásticemi stříbra potencovaných antibiotik v léčbě systémové infekce u klinicky relevantního modelu sepse na velkém zvířeti.

Scientific branches

  • R&D category

    AP - Applied research

  • OECD FORD - main branch

    10606 - Microbiology

  • OECD FORD - secondary branch

    30104 - Pharmacology and pharmacy

  • OECD FORD - another secondary branch

    30108 - Toxicology

  • EE - Microbiology, virology
    FP - Other medical fields
    FR - Pharmacology and apothecary chemistry

Completed project evaluation

  • Provider evaluation

    U - Uspěl podle zadání (s publikovanými či patentovanými výsledky atd.)

  • Project results evaluation

    1. The importance is in the development of new unique nanosystems, proof of the in vitro effectiveness of both the nanoparticles themselves and the combination of silver nanoparticles and antibiotics, without evidence of cytotoxicity towards somatic cells, and proof of restoration of the effects of antibiotics in combination with nanoparticles. In the context of the increasingly frequent occurrence of infections with MDR bacterial strains and the increase in the prevalence of sepsis in risk groups of patients, the potential is very high. 2. The results are original and adequate. 3. The translational significance of the project for a number of fields (intensive care medicine, infectology, microbiology, etc.) of this research is essential in finding new ways to treat MDR infectious strains. 4. The achieved publication results already exceed the planned outputs, however, other achieved results also have great publication potential. 5. Deficiencies were not identified.

Solution timeline

  • Realization period - beginning

    May 1, 2020

  • Realization period - end

    Dec 31, 2023

  • Project status

    U - Finished project

  • Latest support payment

    Apr 28, 2023

Data delivery to CEP

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

  • Data delivery code

    CEP24-MZ0-NU-U

  • Data delivery date

    Jul 3, 2024

Finance

  • Total approved costs

    12,233 thou. CZK

  • Public financial support

    12,233 thou. CZK

  • Other public sources

    0 thou. CZK

  • Non public and foreign sources

    0 thou. CZK

Basic information

Recognised costs

12 233 CZK thou.

Public support

12 233 CZK thou.

100%

Provider

Ministry of Health

OECD FORD

Microbiology

Solution period

01. 05. 2020 - 31. 12. 2023

Similar projects(10)

In vitro, in vivo and in silico study on overcoming bacterial resistance via combination of antibiotics with silver nanoparticles and silver compounds (GA15-22248S) In vitro and in vivo study of antimicrobial activity and toxicity of silver nanoparticles, nanocomposites and materials based on silver nanoparticles (GAP304/10/1316) Use of antimicrobial peptides to treatment of musculoskeletal infections with the help of local carriers used in orthopedics (NT14218)